Pharmaceutical composition containing negundo chastetree fruit extract and application of pharmaceutical composition in promoting wound healing
Through the combination of Huangjing extract, vitamins and chitosan, the inflammatory response is inhibited and fibroblast proliferation is promoted, and the problem of low efficiency of veterinary wound healing materials in the prior art is solved, and rapid and effective wound healing effect is achieved.
Patent Information
- Application Number
- CN202410974516.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-19
- Publication Date
- 2024-11-08
AI Technical Summary
The prior art lacks effective veterinary skin wound treatment materials, which are difficult to effectively promote the healing of animal wounds.
The combination of Huangjing extract with vitamins and chitosan is used to form a pharmaceutical composition for the treatment of skin wounds by inhibiting the inflammatory response and promoting fibroblast proliferation.
It significantly improves wound healing rate, especially in animal wound healing, and can quickly improve the wound healing process and reduce inflammation and scar formation.
Smart Images

Figure CN118903299A_ABST
Abstract
Description
Technical Field
[0001] The present invention generally relates to the field of medical technology, and in particular, to a pharmaceutical composition containing a vitex negundo extract and an application thereof in promoting wound healing. Background Art
[0002] Wound healing or trauma healing is a natural process of regeneration of the skin and epidermal tissues of the body after trauma. Normally, the epidermis and dermis of the skin exist in a state of equilibrium to form a barrier to protect the wound. When the eschar breaks, the normal wound healing process begins rapidly. The basic process includes the following stages: hemostasis, inflammation, proliferation, maturation and remodeling. Wound healing is carried out through a complex set of biochemical procedures, in which the elimination of inflammation and the proliferation of fibroblasts play an important role. Animals, especially domestic pets, often suffer from scratches, bites, lacerations and other wounds when playing or exercising. The importance of companion animals to their owners is self-evident, but the existing technology also lacks effective veterinary materials for treating skin wounds.
[0003] Vitex negundo L., also known as Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk, Vitex stalk
[0004] In recent years, the research and development of natural medicines has received widespread attention at home and abroad. Previous studies have shown that the extracts of Vitex negundo have inhibitory effects on Gram-positive bacteria, Gram-negative bacteria, yeast and Penicillium; Vitex negundo seeds can be used to treat rheumatoid arthritis, and Vitex negundo leaves also have the effects of dispelling heat, removing dampness and harmonizing the middle, which indicates that Vitex negundo is likely to have a strong anti-inflammatory effect.
[0005] In view of this, the present invention is proposed. Summary of the invention
[0006] The first object of the present invention is to provide a use of a Vitex negundo extract in preparing a medicament for promoting wound healing in a subject.
[0007] The second object of the present invention is to provide a pharmaceutical composition, the main active ingredients of which are vitex negundo extract, vitamins and chitosan.
[0008] The third object of the present invention is to provide a material for treating skin wounds, which is loaded with the pharmaceutical composition as described above.
[0009] The present invention first discovered that the extract of Vitex negundo has an important role in promoting wound healing in the treated person, and its implementation mechanism includes: low cytotoxicity, and promoting the proliferation of fibroblasts; inhibiting inflammatory response and promoting wound healing. The extract of Vitex negundo can effectively improve the wound healing effect of humans or animals, especially improve the survival of animals, and may have good commercial value and application prospects in the field of veterinary wound healing drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0010] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0011] Figure 1 Vitex negundo extract promotes the proliferation of fibroblasts;
[0012] Figure 2 Light microscopic images of fibroblast culture in the solvent control group (a) and the vitex negundo extract group (b) after the vitex negundo extract was added for 72 hours;
[0013] Figure 3 The effects of different groups on wound healing rate; *, vs E group, P<0.05; **, vs E group, P<0.01; #, vs A group, P<0.05; ##, vs A group, P<0.01;
[0014] Figure 4 The differences in IFN-γ and TNF-α mRNA levels in different groups after administration on the 6th day; *, vs group E, P<0.05; ***, vs group E, P<0.001; #, vs group A, P<0.05; ##, vs group A, P<0.01. DETAILED DESCRIPTION
[0015] References to embodiments of the present invention will now be provided in detail, one or more examples of which are described below. Each example is provided as an explanation rather than a limitation of the present invention. In fact, it will be apparent to those skilled in the art that various modifications and variations may be made to the present invention without departing from the scope or spirit of the present invention. For example, a feature illustrated or described as part of one embodiment may be used in another embodiment to produce a further embodiment.
[0016] Unless otherwise indicated, the meaning of all terms (including technical and scientific terms) used to disclose the present invention is the same as that commonly understood by those of ordinary skill in the art to which the present invention belongs. By way of further guidance, the following definitions are used to better understand the teachings of the present invention. The terms used herein in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention.
[0017] The terms "and / or", "or / and", and "and / or" used in this article include any one of two or more related listed items, and also include any and all combinations of related listed items, and the arbitrary and all combinations include any two related listed items, any more related listed items, or a combination of all related listed items. It should be noted that when at least three items are connected by at least two conjunctions selected from "and / or", "or / and", and "and / or", it should be understood that in this application, the technical solution undoubtedly includes technical solutions that are all connected by "logical and", and undoubtedly includes technical solutions that are all connected by "logical or". For example, "A and / or B" includes three parallel solutions of A, B and A+B. For example, the technical solution of "A, and / or, B, and / or, C, and / or, D" includes any one of A, B, C, and D (that is, the technical solution that is all connected by "logical OR"), and also includes any and all combinations of A, B, C, and D, that is, the combination of any two or any three of A, B, C, and D, and also includes the combination of four of A, B, C, and D (that is, the technical solution that is all connected by "logical AND").
[0018] As used herein, the terms "comprising", "including" and "comprising" are synonymous and are inclusive or open-ended and do not exclude additional, unrecited members, elements or method steps.
[0019] Numerical ranges expressed as endpoints herein include all numbers and fractions subsumed within the range, as well as the recited endpoints.
[0020] The present invention relates to concentration values, and its meaning includes fluctuations within a certain range. For example, it can fluctuate within the corresponding accuracy range. For example, 2% can allow fluctuations within the range of ±0.1%. For values that are large or do not require too fine control, its meaning is also allowed to include greater fluctuations. For example, 100mM can allow fluctuations within the range of ±1%, ±2%, ±5%, etc. Involving molecular weight, its meaning is allowed to include fluctuations of ±10%.
[0021] In the present invention, descriptions such as "plurality" and "multiple" refer to quantities greater than or equal to 2 unless otherwise specified.
[0022] In the present invention, the technical features described in an open manner include closed technical solutions composed of the listed features, and also include open technical solutions containing the listed features.
[0023] In the present invention, "preferably", "better", "more preferably", and "suitably" are only used to describe implementation methods or examples with better effects, and it should be understood that they do not constitute a limitation on the scope of protection of the present invention. In the present invention, "optionally", "optional", and "optional" refer to being optional, that is, any one of the two parallel schemes of "yes" or "no". If multiple "options" appear in a technical solution, unless otherwise specified and there is no contradiction or mutual restriction, each "optional" is independent of each other.
[0024] As used herein, the term "wound" includes damage to any tissue, including, for example, delayed or difficult to heal wounds and chronic wounds. Examples of wounds may include open and closed wounds. The term "wound" may also include, for example, damage to the skin and subcutaneous tissue, which is caused in different ways (e.g., bedsores caused by long-term bed rest and wounds caused by trauma) and has different characteristics. Depending on the depth of the wound, the wound can be classified into one of four levels: i) Level I (I grade) wounds, limited to the epithelium; ii) Level II wounds, extending to the dermis; iii) Level III wounds, extending to the subcutaneous tissue; and iv) Level IV (or full-thickness wounds) wounds, wherein bones are exposed (e.g., bone pressure points such as greater trochanter or sacrum). More specific examples are diabetic ulcers, vasculitic ulcers, arterial ulcers, venous ulcers, pressure ulcers, infected ulcers, trauma-induced ulcers, burn ulcers, ulcers associated with pyoderma gangrenosum, or mixed ulcers.
[0025] As used herein, delayed or poorly healing wounds may include, for example, wounds characterized at least in part by: 1) a prolonged inflammatory phase, 2) slow formation of extracellular matrix, and / or 3) a reduced rate of epithelialization or closure.
[0026] The term "chronic wound" generally refers to a wound that has not healed. Wounds that have not healed within three months are, for example, considered chronic. Chronic wounds include venous ulcers, venous stasis ulcers, arterial ulcers, pressure ulcers, diabetic ulcers, diabetic foot ulcers, vasculitic ulcers, decubitus ulcers, burn ulcers, trauma-induced ulcers, infected ulcers, mixed ulcers, and pyoderma gangrenosum. Chronic wounds can be arterial ulcers, including ulcers caused by complete or partial arterial occlusion. Chronic wounds can be venous or venous stasis ulcers, including ulcers caused by venous valve dysfunction and related vascular diseases. In certain embodiments, a method for treating chronic wounds is provided, wherein the chronic wound is characterized by one or more of the following AHCPR stages of pressure ulcers: stage 1, stage 2, stage 3, and / or stage 4.
[0027] As used herein, a chronic wound may refer to, for example, a wound characterized at least in part by one or more of the following: (1) a chronic, self-perpetuating state of wound inflammation, (2) an inadequate and defective wound extracellular matrix, (3) adversely responsive (senescent) wound cells, particularly fibroblasts, which limit extracellular matrix production, and / or (4) failure to re-epithelialize, in part due to a lack of necessary extracellular matrix orchestration and a lack of scaffolding for migration. Chronic wounds are also characterized by: 1) long-term inflammatory and proteolytic activity, which leads to ulcerative lesions, including, for example, diabetic, pressure (decubitus), venous, and arterial ulcers; 2) progressive deposition of matrix in the affected area, 3) longer repair time, 4) less wound contraction, 5) slower re-epithelialization, and 6) increased thickness of granulation tissue.
[0028] Exemplary chronic wounds may include "pressure (compression) ulcers." Based on AHCPR (Agency for Health Care Policy and Research, U.S. Department of Health and Human Services) guidelines, exemplary pressure ulcers may be divided into 4 stages. Stage I pressure ulcers are significant pressure-related changes in intact skin, indicators of which may include changes in one or more of the following compared to adjacent or opposing areas on the body: skin temperature (warmth or coolness), tissue consistency (firm or soft and clammy feeling), and / or sensation (pain, itching). Ulcers appear as defined areas of persistent redness in light-pigmented skin, while ulcers may appear as persistent red, blue, or purple hues in darker skin tones. Stage 1 ulcers may include non-fading erythema of intact skin and precursor lesions of skin ulcers. In individuals with darker skin tones, skin discoloration, warmth, edema, hardening, or firmness may also be indicators of a Stage 1 ulcer. Stage 2 ulcers may be characterized by partial thickness skin loss involving the epidermis, dermis, or both. The ulcer is superficial and clinically manifests as an abrasion, blister, or shallow cut (or shallow depression). Stage 3 ulcers may be characterized by full thickness skin loss involving damage or necrosis of subcutaneous tissue that may extend down to, but not through, the underlying fascia. The ulcer clinically manifests as a deep cut (or deep depression) with or without adjacent tissue destruction. Stage 4 ulcers may be characterized by full thickness skin loss with extensive destruction, tissue necrosis, or damage to muscle, bone, or supporting structures (e.g., tendons, joint capsules). In certain embodiments, a method for treating a chronic wound is provided, wherein the chronic wound is characterized by one or more of the following AHCPR stages of a pressure ulcer: stage 1, stage 2, stage 3, and / or stage 4.
[0029] Exemplary chronic wounds may also include "decubitus ulcers". Exemplary decubitus ulcers may be caused by prolonged and unrelieved pressure on a bony prominence, which results in ischemia. The wound tends to occur in patients who are unable to change their position to unload weight, such as paralyzed, unconscious, or severely disabled people. As defined by the U.S. Department of Health and Human Services, primary preventive measures include identification of high-risk patients; frequent assessments; and preventive measures such as regular position changes, appropriate pressure-reducing bedding, moisture-proof layers, and proper nutritional status. Treatment options may include, for example, decompression, surgical and enzymatic debridement, moist wound care, and control of bacterial load. In certain embodiments, a method for treating a chronic wound is provided, wherein the chronic wound is characterized by decubitus ulcers or ulcer formation, which comes from prolonged, unrelieved pressure on a bony prominence, which results in ischemia.
[0030] Chronic wounds may also include "arterial ulcers." Chronic arterial ulcers are generally understood to be ulcers associated with arteriosclerosis and hypertensive cardiovascular disease. They are painful, sharply marginated, and often present on the lateral lower extremities and toes. Arterial ulcers may be characterized by complete or partial arterial occlusion, which may lead to tissue necrosis and / or ulceration. Signs of arterial ulcers may include, for example, pulselessness in the extremities; painful ulcers; small, punctate ulcers that are usually well defined; cool or cold skin; delayed capillary return time (quickly squeeze the toe tip and release, normal color should return to the toe in about 3 seconds or less); atrophic-looking skin (e.g., shiny, thin, dry); and loss of finger and foot hair. In certain embodiments, a method of treating a chronic wound is provided, wherein the chronic wound is characterized by an arterial ulcer or ulceration caused by complete or partial arterial occlusion.
[0031] Exemplary chronic wounds may include "venous ulcers". Exemplary venous ulcers are the most common type of ulcer affecting the lower extremities and may be characterized by venous valve dysfunction. Normal veins have valves that prevent the backflow of blood. When these valves become incapable, the backflow of venous blood causes venous congestion. Hemoglobin from red blood cells escapes and leaks into the extravascular space, causing the brown discoloration that is often noticed. It has been shown that the transcutaneous oxygen tension of the skin around venous ulcers is reduced, suggesting that there are forces that hinder the normal vascular distribution of the area. Lymphatic drainage and flow also play a role in these ulcers. Venous ulcers can occur near the medial malleolus and often occur in conjunction with edema and indurated lower extremities; it can be shallow, less painful and may present as a leaky discharge from the affected area. In certain embodiments, a method of treating a chronic wound is provided, wherein the chronic wound is characterized by a venous ulcer or ulceration caused by venous valve dysfunction and related vascular disease. In certain embodiments, a method of treating a chronic wound is provided, wherein the chronic wound is characterized by an arterial ulcer or ulceration caused by complete or partial arterial occlusion.
[0032] Exemplary chronic wounds may include "venous stasis ulcers". Stasis ulcers are lesions associated with venous insufficiency and are more commonly found on the medial malleolus, typically with pitting edema, varicose veins, macular pigmentation, erythema, and non-palpable petechiae and purpura. Stasis dermatitis and ulcers are typically pruritic rather than painful. Exemplary venous stasis ulcers may be characterized by chronic passive venous congestion of the lower extremities, which results in localized hypoxia. One possible pathogenesis of these wounds includes obstruction of oxygen diffusion into the tissues through the thick perivascular fibrin cuff. Another mechanism is that macromolecules leaking into the perivascular tissues capture growth factors required to maintain skin integrity. In addition, due to venous congestion, the flow of larger leukocytes is slowed, thereby blocking capillaries, becoming activated, and damaging the vascular endothelium, thereby predisposing to ulcer formation. In certain embodiments, a method for treating a chronic wound is provided, wherein the chronic wound is characterized by venous ulcers or ulcer formation caused by venous valve dysfunction and related vascular diseases. In certain embodiments, a method of treating a chronic wound is provided, wherein the chronic wound is characterized by venous stasis ulcers or ulcerations caused by chronic passive venous congestion of the lower extremities and / or the resulting localized hypoxia.
[0033] Exemplary chronic wounds may include "diabetic ulcers". Diabetics are susceptible to ulcers, including foot ulcers, which arise from neurological and vascular complications. Peripheral neuropathy can cause altered or complete loss of sensation in the feet and / or legs. Diabetics with advanced neuropathy have reduced ability to distinguish between all agile and slow. Any wound or trauma to the foot may go completely unnoticed for days or weeks in neuropathy patients. It is not uncommon for neuropathy patients to notice that an ulcer "just appeared" when in fact the ulcer has been present for quite some time. For neuropathy patients, strict blood sugar control has been shown to slow the progression of the disease. Charcot foot deformity may also occur due to reduced sensation. People with "normal" sensation in their feet have the ability to automatically sense when too much pressure is being applied to the foot area. Once determined, our bodies instinctively move positions to relieve the stress. Patients with advanced neuropathy have reduced ability to sense continued pressure damage, and thus, tissue ischemia and necrosis may occur, leading to, for example, plantar ulcers. In addition, microfractures in the bones of the foot, if not noticed and treated, can lead to disfigurement, chronic swelling, and additional bony prominences. Microvascular disease is one of the major complications of diabetic patients, which can also lead to ulcer formation. In certain embodiments, a method for treating a chronic wound is provided, wherein the chronic wound is characterized by diabetic foot ulcers and / or ulcer formation caused by the neurological and vascular complications of diabetes.
[0034] Exemplary chronic wounds may include "traumatic ulcers". The formation of traumatic ulcers may result from traumatic injury to the body. These injuries include, for example, damage to the arteries, veins, or lymphatic system; changes in the bone structure of the skeleton; loss of the tissue layers epidermis, dermis, subcutaneous soft tissue, muscle or bone; damage to a body part or organ and loss of a body part or organ. In certain embodiments, a method of treating a chronic wound is provided, wherein the chronic wound is characterized by ulceration associated with a traumatic injury to the body.
[0035] Exemplary chronic wounds may include "burn ulcers," which include first-degree burns (i.e., superficial, reddened areas of skin); second-degree burns (sites of blister lesions that may heal spontaneously after blister fluid has been removed); third-degree burns (burns that extend through the entire skin and usually require surgical intervention for wound healing); scalds (can result from scalding hot water, grease, or radiator fluid); thermal burns (can result from flames, and are usually deep burns); chemical burns (can result from acids and bases, and are usually deep burns); electrical burns (low voltage around the house or high voltage at work); explosive flames (usually superficial injuries); and contact burns (usually deep burns and can result from muffler tail pipes, hot irons, and stoves). In certain embodiments, a method of treating a chronic wound is provided, wherein the chronic wound is characterized by ulceration associated with a burn injury to the body.
[0036] Exemplary chronic wounds may include "vasculitic ulcers." Vasculitic ulcers also occur on the lower extremities and are painful, sharp-edged lesions that may have associated palpable purpura and hemorrhagic bullae. Collagen diseases, sepsis, and various blood disorders (e.g., thrombocytopenia, dysproteinemia) may be causes of this severe, acute condition.
[0037] Exemplary chronic wounds may include pyoderma gangrenosum. Pyoderma gangrenosum is present as a single or multiple very immature ulcers of the lower leg. A deep red to purple destructive border surrounds a purulent central defect. Biopsy typically does not reveal vasculitis. In half of the patients, it is associated with systemic diseases such as ulcerative colitis, Crohn's disease, or leukemia. In certain embodiments, a method for treating a chronic wound is provided, wherein the chronic wound is characterized by ulcer formation associated with pyoderma gangrenosum.
[0038] Exemplary chronic wounds may include infected ulcers. Infectious ulcers occur after direct inoculation of various organisms and may be accompanied by significant regional adenopathy. Examples are mycobacterial infection, anthrax, diphtheria, blastomycosis, sporotrichosis, tularemia, and cat scratch fever. Genital ulcers of primary syphilis are usually non-tender and have a clean, solid base. Those genital ulcers of chancroid and inguinal granuloma tend to be rough, dirty, and more extravagant lesions. In certain embodiments, a method for treating chronic wounds is provided, wherein the chronic wound is characterized by ulcer formation associated with infection.
[0039] As used herein, the term "dehiscent wound" refers to a wound, typically a surgical wound, that has a ruptured or split opening. In certain embodiments, a method of treating a wound that does not heal at an expected rate is provided, wherein the wound is characterized by dehiscence.
[0040] The present invention relates to the use of a vitex negundo extract in preparing a medicament for promoting wound healing of a subject.
[0041] In some embodiments, the Vitex negundo extract is used in combination with vitamins and chitosan.
[0042] In some embodiments, the Vitex negundo extract is an aqueous extract of Vitex negundo callus.
[0043] As used herein, "subject" refers to any mammal, including humans, domestic and farm animals (or livestock), and zoo animals, sports animals, or pets, such as dogs, horses, cats, sheep, pigs, cows, etc. Preferred mammals herein are humans, including adults, children, and the elderly.
[0044] According to another aspect of the present invention, it also relates to a pharmaceutical composition, the main active ingredients of which are vitex negundo extract, vitamins and chitosan.
[0045] In some embodiments, the mass ratio of the vitex negundo extract, vitamins and chitosan is (1-10): (1×10 -4 ~1×10 -6 ):(10~50), and the most preferred is 1:1×10 -5 :30.
[0046] In some embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
[0047] The term "pharmaceutically acceptable carrier" refers to any pharmaceutical carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition and that can be administered without undue toxicity. Suitable carriers can be larger, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, and amino acid copolymers.
[0048] Pharmaceutically acceptable salts may also be present, for example, inorganic acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, and the like; and organic acid salts such as acetates, propionates, malonates, benzoates, and the like.
[0049] In some embodiments, the pharmaceutical composition is a solution, and the final concentration of the Vitex negundo extract in the pharmaceutical composition is 0.7 mg / mL to 1.3 mg / mL; it can also be 0.8 mg / mL, 0.9 mg / mL, 1.0 mg / mL, 1.1 mg / mL, or 1.2 mg / mL.
[0050] In some embodiments, the vitamin is vitamin D.
[0051] In some embodiments, the pharmaceutical composition is a solution containing 0.5 wt% to 5 wt% carboxymethyl cellulose and 0.1 wt% to 2 wt% poloxamer.
[0052] The medicament of the present invention can be administered to a subject in need of treatment, such as a subject suffering from any wound mentioned herein. Thus, the condition of the subject can be improved. Through treatment, the pharmaceutical composition can be used for the treatment of the subject's body. They can be used to prepare a medicament for treating any wound mentioned herein. Pharmaceutical carriers or vehicles suitable for the pharmaceutical composition of the present invention include any of those commonly used for topical administration. Topical preparations can be, for example, in the form of creams, ointments, gels, emulsions, lotions, sprays, foams or paints. The preparations of the present invention can also exist in the form of impregnated dressings.
[0053] According to yet another aspect of the present invention, it also relates to a material for treating skin wounds, which is loaded with the pharmaceutical composition as described above.
[0054] In some embodiments, the material is a veterinary material for treating skin wounds.
[0055] In the present invention, "beast" or "animal" refers to non-human mammals, such as dogs, cats, rabbits, mice (such as hamsters, guinea pigs, chinchillas, gerbils), ferrets, horses, sheep, cattle, foxes, monkeys, giant pandas, and pigs; in particular, the above-mentioned animals in the present invention are domestic animals, that is, animals that are raised and domesticated by humans and whose reproduction can be artificially controlled, and are used for functions such as food, labor, fur, pets, experiments, etc., such as economic animals, pets, experimental animals, etc.; more preferred are companion animals, especially dogs and cats.
[0056] The material can be attached to or otherwise combined with the skin of the subject, and the article can deliver a therapeutically effective amount of the pharmaceutical composition. In some embodiments, the material is a transdermal patch, dressing, pad, wrap, matrix or bandage.
[0057] Various forms of the above materials can be prepared according to conventional production methods in the field of veterinary functional medicines.
[0058] As used herein, a "therapeutically effective amount" of a compound or composition of the invention refers to an amount sufficient to induce a desired biological, pharmaceutical, or therapeutic outcome. The outcome may be a reduction in the signs, symptoms, or causes of a disease or disorder or condition, or any other desired change in a biological system. In the present invention, the outcome will relate to wound healing, including promotion and / or improvement of wound healing rate and closure (in whole or in part) of a wound. Other benefits include a total or partial reduction in swelling, inflammation, and / or scarring.
[0059] The method of administering the pharmaceutical composition or the material may be: continuously administering the pharmaceutical composition or the material to the wound (or the area in or around the wound). Repeated application is included in the present invention. Preferably, the application is repeated until wound closure is seen to be proceeding, and then the application is repeated once (or multiple times) if wound healing becomes stalled or delayed again.
[0060] The active ingredients in the compositions and methods of the invention can also be determined by reference to the concentration of the composition relative to the size, length, depth, area or volume of the area to be applied. For example, in certain local and other uses, such as instillation, the dosage of the pharmaceutical composition can be calculated based on the mass (e.g., micrograms) or concentration (e.g., μg / μl) of the pharmaceutical composition per length, depth, area, or volume of the application area.
[0061] As noted, for example, one or more formulations of the invention may be administered prior to, during, immediately after, or, for example, within about 180 or more, about 120, about 90, about 60, or about 30 days of the injury.
[0062] The routes of administration and dosages described herein are intended only as a guide, as the skilled physician will determine the best route and dosage for any particular patient and wound.
[0063] Embodiments of the present invention will be described in detail below in conjunction with examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples that do not specify specific conditions are preferably referred to the guidance provided in the present invention, and can also be based on the experimental manual or normal conditions in this area, and can also be based on other experimental methods known in the art, or according to the conditions recommended by the manufacturer.
[0064] In the following specific embodiments, the measured parameters of raw material components may have slight deviations within the range of weighing accuracy unless otherwise specified. For temperature and time parameters, acceptable deviations caused by instrument test accuracy or operation accuracy are allowed.
[0065] Example 1 Obtaining Vitex Ngawaii Callus and Preparing Extracts
[0066] 1. Cultivation of callus tissue of Vitex negundo
[0067] The vitex negundo callus used in the present invention can be obtained by a known method or any existing technology that can obtain vitex negundo callus, such as the method described in Chinese patent documents with application numbers 202011604196.7 or 202011604180.6.
[0068] In this embodiment, callus tissue is prepared by the following method.
[0069] 1). Materials
[0070] On a clear summer morning, semi-lignified paper strips with 4-6 axillary buds from healthy adult plants of Vitex negundo were collected as explants.
[0071] After washing the explants, their surfaces were sterilized, soaked in 70% alcohol solution for 30 seconds, 0.1% HgCl2 for 5 minutes, rinsed 5 times with sterile water, and then cut into 2-5 cm long stem segments with 2-3 axillary buds.
[0072] 2). Culture medium and culture conditions
[0073] The experiment used 1 / 2MS as the basic culture medium, with a sucrose concentration of 30g / L, an agar concentration of 10g / L, a pH of 6.1, and added 2,4-D 1.2μM, 6-BA 0.20μM, TDZ 0.20μM, vitamin C 25mg / L and inositol 30mg / L. The culture temperature was (25±2)℃, the light intensity was 2100lx, the light time was 12h, and the relative humidity was 55%. The callus tissue was collected on the 10th day of culture.
[0074] 2. Preparation of Vitex Neem Extract
[0075] Fresh callus tissue (2.0-2.5 g) obtained from the above culture was taken, accurately weighed, ground and crushed by a grinder (60 Hz, 60 s×2 times), then added with 10 times the volume of deionized water, ultrasonically extracted at 700 W for 20 min, centrifuged at 5000 rpm for 30 min, and the supernatant was taken and filtered at 0.45 uM to obtain a vitex negundo extract. Among them, the average solid content of the extract was 4.36±0.78 mg / mL, calculated based on 20 extractions.
[0076] Example 2 Vitex negundo extract promotes proliferation of fibroblasts
[0077] 1. Isolation and Culture of Fibroblasts
[0078] The normal skin fibroblasts used in the experiment were derived from healthy human skin and were cultured for 5 to 10 generations using the tissue patch method.
[0079] 2. Screening of the Optimal Growth Concentration
[0080] MTT colorimetric analysis was used. Fibroblasts in logarithmic growth phase were seeded in 96-well plates at a density of 3000 / cm2, 200 μL per well, and incubated in an incubator at 37°C, 5% CO2 for 48 h. After the cells were completely attached to the wall, the culture medium was discarded, and group A was added with different concentrations (0.125, 0.25, 0.5, 1.0, 2.0, 4.0 mg / mL) of Vitex negundo extract conditioned medium (150 μL / well), group B was added with DMEM containing 10 mg / mL DMSO (150 μL / well), and group C was added with DMEM culture medium (150 μL / well), and each group had 6 parallel wells. After culturing for 24 h, add 10 μL of 5 mg / mL MTT reagent to each well, incubate in the incubator for 4 h, discard the culture medium, add DMSO (150 μL / well), shake for 10 min, and read the light absorption value A at a wavelength of 450 m using an enzyme-linked immunosorbent assay.
[0081] After the culture medium of each group acted on fibroblasts for 24 hours, it was observed that the light absorption value A of group A was significantly higher than that of group C when the concentration was 0.25 mg / mL~4.0 mg / mL (P<0.05), and showed an obvious concentration dependence in the range of 0.25 mg / mL~1.0 mg / mL. The light absorption value A was the highest at 1.0 mg / mL. Therefore, 1.0 mg / mL was taken as the optimal concentration of Nephrolepis cochinchinensis extract to promote the proliferation of fibroblasts.
[0082] 3. Fibroblast Growth Curve
[0083] When fibroblasts were cultured at a concentration of 1.0 mg / mL of N. cerevisiae extract, it was observed that the A value of the N. cerevisiae extract group was significantly higher than that of the solvent control group 12 hours after the addition of the drug. As the culture time increased, the difference between the two groups gradually increased until 36 hours. 36 hours was the peak of the A value of the N. cerevisiae extract group and the solvent control group, and the difference between the two groups was most significant at this time. From 36 to 72 hours, the A values of the two groups gradually decreased, but the N. cerevisiae extract group was still higher than the solvent control group ( Figure 1 ). The light microscopic results of the cells after 72 hours of culture are as follows Figure 2 shown.
[0084] This example also illustrates that the Vitex negundo extract has no or only very little cytotoxicity.
[0085] Example 3: Vitex negundo extract promotes wound healing
[0086] 1. Establishment of Animal Model
[0087] The rat skin excision injury model was established according to the literature (Leite SN, et al. Fitoterapia. 2002 Oct; 73(6): 496-500). Healthy male SD rats weighing 250 g to 280 g were treated with 3% sodium pentobarbital (30 mg kg -1 ) Intraperitoneal injection of anesthesia, back hair removal, routine disinfection. On both sides of the spine, a corneal trephine was used to cut a radius of 16 cm and an area of 400 mm 2 The wound surface was exposed after modeling and the rats were kept in single cages.
[0088] 2. Grouping and Dosing
[0089] Group A: The concentration of Vitex negundo extract, vitamin D and chitosan was 1:1×10 -5 :30, the temperature was raised to 60°C, carboxymethyl cellulose and poloxamer were added in sequence, and the mixture was fully dissolved and set aside for use, wherein the final concentration of the vitex negundo extract was 1.0 mg / mL, the final concentration of the methyl cellulose was 1 wt%, and the final concentration of the poloxamer was 1 wt%.
[0090] Group B: The preparation method was the same as that of Group A, except that vitamin D and chitosan were not added;
[0091] Group C: The preparation method was the same as that of Group A, except that no Vitex negundo extract was added;
[0092] Group D (solvent control group): The preparation method was the same as that of group A, except that no vitex negundo extract, vitamin D and chitosan were added;
[0093] Group E (blank control group): The same amount of normal saline as that of group A was given.
[0094] The rats were randomly divided into five groups, 8 in each group, and were administered with drugs from groups A to E, with the application volume of 100 μL per day.
[0095] 3. Detection Methods
[0096] Effect of drugs on wound healing rate: The wound healing rates of rats were calculated on days 6, 12, 18, and 24 after injury. Healing rate = (original wound area - unhealed wound area) / original wound area.
[0097] 4. Test results
[0098] like Figure 3 As shown, on the 6th day of administration, the wound healing rate of Group A had reached 62.8%, which was significantly different from that of Group E (two-way ANOVA, P<0.01). This difference continued until the end of treatment on the 24th day, when the wound healing rate reached 100%.
[0099] Similarly, group B also had significant differences compared with group E on days 6 to 24, and group C also had significant differences compared with group E on days 12 to 24; but the initial healing speed of both groups was slower than that of group A. On days 6 to 12, both groups B and C had significant differences compared with group A. This shows that the mixed formula of group A can quickly induce wound healing, allowing patients to have a very good treatment experience.
[0100] Example 4 The combination of Vitex negundo extract, vitamin D and chitosan can promote early rapid healing of wounds by inhibiting inflammatory response
[0101] To further explore the reasons for the rapid healing of Group A in Example 3, we repeated the above experiment with 6 animals in each group, and killed the animals on the 6th day when the difference in healing rates among Groups ABC was the largest. We collected tissues from the animal wounds and extracted RNA. We used RT-PCR to detect changes in the expression levels of IFN-γ and TNF-α in the animal tissues.
[0102] The detection method is as follows:
[0103] 1. Tissue RNA Extraction
[0104] 1) Preparation: Soak EP tubes, 1 ml pipette tips, and yellow pipette tips in non-autoclaved DEPC water at 37° overnight and then remove residual DEPC by autoclaving.
[0105] 2) Sample processing: Take fresh tissue, add 1 mL TRNzol-A+ for every 30 mg to 50 mg of tissue and grind with a glass homogenizer. Note that the total volume of the sample should not exceed 10% of the volume of Trizol used.
[0106] 3) The grinding solution is placed at room temperature for 5 minutes to completely separate the nucleic acid-protein complex.
[0107] 4) Centrifuge at 14000 rpm for 10 min at 4°C and transfer the supernatant to a new EP tube.
[0108] 5) Add 0.2 ml of chloroform per 1 ml of Trizol solution, cover the centrifuge tube tightly, shake the centrifuge tube vigorously for 15 seconds, and leave it at room temperature for 3 minutes.
[0109] 6) Centrifuge at 4°C, 14000rpm for 10-15min. The sample is separated into three layers: a yellow organic phase, an intermediate layer, and an upper colorless aqueous phase. Transfer the aqueous phase to a new EP tube. Add an equal volume of isopropanol, mix well, and place at -20° for 20-30min.
[0110] 7) Centrifuge at 4°C, 14,000 rpm for 10 min and discard the supernatant. After centrifugation, a gelatinous precipitate may form on the side wall or bottom of the tube, but it may not be visible.
[0111] 8) Add at least 1 mL of pre-cooled 75% ethanol to 1 mL of Trizol solution, invert and mix to wash the precipitate (ethanol is prepared with DEPC water).
[0112] 9) Centrifuge at 14,000 rpm for 10 minutes at 4°C and carefully discard the supernatant.
[0113] 10) Then dry at room temperature or under vacuum for 5 to 10 minutes. Be careful not to over-dry, otherwise the solubility of RNA will be reduced. Then dissolve RNA in water, at 55℃ to 60℃ for 10 minutes if necessary.
[0114] 11) Add 30-100 μL DEPC water, pipette and mix repeatedly to fully dissolve the RNA.
[0115] 12) Gel running: marker: DL2000 5μL
[0116] Sample addition: 6× loading buffer 1μL
[0117] Formamide 4 μL
[0118] RNA 2 μL
[0119] After mixing, add
[0120] Glue: 1.8% with EB 120V 15min
[0121] 2. RNA Concentration Determination
[0122] Take 1 μL RNA and measure the concentration using a spectrophotometer OD260 / 280 ratio.
[0123] 3. Reverse Transcription Reaction
[0124] 1) Preparation: Preparation of mixture on ice:
[0125] Total RNA 0.1μg~5μg (usually 0.5μg is sufficient) Random primer (0.5μg / μL) 1μL DEPC water added to 11μL
[0126] Mix well and centrifuge for 3 to 5 seconds.
[0127] 2) Incubate at 65°C for 5 min. Cool on ice and centrifuge briefly.
[0128] 3) Add in sequence:
[0129] 5×reaction buffer 4μL
[0130] RiboLock Ribonuclease Inhibitor(20μg / μL)1μL
[0131] 10mM dNTPmix 2μL
[0132] Mix well and centrifuge briefly.
[0133] 4) Incubate at 37°C for 5 min
[0134] 5) Add 2 μL of M-MuLV reverse transcriptase (20u / μL) to a total volume of 20 μL.
[0135] 6) Room temperature for 5 minutes.
[0136] 7) Incubate at 42°C for 60 min.
[0137] 8) Heat at 70°C for 10 min to terminate the reaction. Cool on ice.
[0138] 9) The reverse transcribed DNA can be stored at -20℃.
[0139] 4. Real-time Quantitative PCR
[0140] 1) Reaction system:
[0141]
[0142] A total of 20 μL system, after adding the sample, centrifuge <2000rbpm 2)
[0144] Primer sequences
[0145]
[0146] Reaction conditions:
[0147] 95℃30s
[0148] 95℃0s
[0149] Annealing temperature 5s
[0150] 72℃10s
[0151] 40 cycles
[0152] 95℃0s
[0153] 65℃30s
[0154] 95℃0.1 / Continuous cooling
[0155] 40℃30s
[0156] 5. Test results such as Figure 4As shown in the figure, ANOVA analysis of variance showed that in the detection of IFN-γ mRNA expression, compared with group E, group A had a significant decrease (P<0.001), and group B also had a decrease (P<0.05); in the detection of TNF-α, similarly, compared with group E, group A had a significant decrease (P<0.001), while there were no differences in other parameters.
[0157] In addition, compared with group A, groups B and C showed significant differences in the detection of two inflammatory factors.
[0158] The above experimental results indicate that the combination of the Vitex negundo extract of the present application with vitamin D and chitosan can more quickly and effectively promote early wound healing by inhibiting inflammatory response.
[0159] The above-mentioned embodiments only express several implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the invention patent. It should be pointed out that for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be based on the attached claims, and the description and drawings can be used to interpret the content of the claims.
Claims
1. Use of a Vitex negundo extract in the preparation of a medicament for promoting wound healing in a subject; Preferably, the Vitex negundo extract is used in combination with vitamins and chitosan.
2. The use according to claim 1, characterized in that: The Vitex negundo extract is a water extract of Vitex negundo callus.
3. The use according to claim 1 or 2, characterized in that: The subject is a dog, horse, cat, sheep, pig, cow, or human.
4. A pharmaceutical composition, characterized in that The main active ingredients are Vitex negundo extract, vitamins and chitosan.
5. The pharmaceutical composition according to claim 4, characterized in that The mass ratios of the vitex negundo extract, vitamins and chitosan are (1-10): (1×10 -4 ~1×10 -6 ):(10~50); preferably, the pharmaceutical composition is a solution, and the final concentration of the Nephrolepis nigrum extract in the pharmaceutical composition is 0.7mg / mL~1.3mg / mL.
6. The pharmaceutical composition according to claim 5, characterized in that The vitamin is vitamin D.
7. The pharmaceutical composition according to claim 4, characterized in that It also contains a pharmaceutically acceptable carrier; preferably, it is a solution and further contains 0.5wt% to 5wt% of carboxymethyl cellulose and 0.1wt% to 2wt% of poloxamer.
8. The pharmaceutical composition according to any one of claims 4 to 7, characterized in that It is in the form of a cream, ointment, gel, emulsion, lotion, spray, foam or paint.
9. A material for treating skin wounds, characterized in that: The material is loaded with the pharmaceutical composition according to any one of claims 4 to 8; preferably it is a material for treating skin wounds for animals.
10. The material according to claim 9, characterized in that It is a transdermal patch, dressing, pad, wrap, matrix or bandage.
Citation Information
Patent Citations
Vitex negundo test-tube plantlet rapid propagation method
CN112493137A
Vitex negundo callus induction method
CN112741001A
